Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
US Department of Justice
Chinese Patent Office

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,444,434

« Back to Dashboard

Title: FVIIa/TF activity inhibiting compounds
Abstract:The invention relates to compounds inhibiting the activation of FX to FXa by TF/FVIIa. The compounds are anticoagulants. The invention also relates to a method of identifying a drug candidate.
Inventor(s): Jakobsen; Palle (Vaerl.o slashed.se, DK), Persson; Egon (.ANG.karp, SE)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Filing Date:Apr 27, 2001
Application Number:09/844,828
Claims:1. A compound having an inhibitory action on Factor VII-Tissue Factor (FVII-TF) activity, wherein said compound exhibits: (i) half-maximal inhibition at a concentration of 20 .mu.M or less in a FX activation assay, (ii) half-maximal inhibition at a concentration of 100 .mu.M or more in a FXa amidolytic assay, and (iii) half-maximal inhibition at a concentration of 20 .mu.M or more in a TF/FVIIa amidolytic assay.

2. A compound as defined in claim 1, wherein said compound further exhibits clotting activity corresponding to a clot ratio of more than 1 in a FVIIa/TF-initiated clotting assay.

3. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier or excipient.

4. A method for treatment of a FVIIa/TF-related disease or disorder in a subject, which method comprises administering an effective amount of at least one compound according to claim 1 to a subject in need of such treatment.

5. A method according to claim 4, wherein the FVIIa/TF-related disease or disorder is selected from the group consisting of: deep venous thrombosis, arterial thrombosis, post surgical thrombosis, coronary artery bypass graft (CABG), percutaneous transdermal coronary angioplastry (PTCA), stroke, tumour metastasis, angiogenesis, thrombolysis, arteriosclerosis and restenosis following angioplastry, inflammation, septic chock, septicemia, hypotension, adult respiratory distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC), pulmonary embolism, platelet deposition, myocardial infarction, and a disease or disorder requiring one or more of dialysis procedures, blood filtration, or blood bypass during surgery.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Daiichi Sankyo
Harvard Business School
Johnson and Johnson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.